Clinical trials: sponsored by Eli Lilly and Company
Advanced Cancer
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.
- Trial name
- NCT03936959
- Testing
- LY3434172
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Healthy
A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants
This study is being conducted to determine the side effects related to LY3493269 given as a single injection to healthy participants.
- Trial name
- NCT04178733
- Testing
- LY3493269 - SC, LY3493269 - IV
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Safety Study of LY3493269 in Healthy Participants
The main purpose of this study in healthy participants is to learn more about the safety of LY3493269 and any side effects that might be associated with it.
- Trial name
- NCT04498390
- Testing
- LY3493269
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY3493269 in Participants With Type 2 Diabetes
The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream.
- Trial name
- NCT04515576
- Testing
- LY3493269, Dulaglutide
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3493269 in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3493269 in healthy participants. The blood tests will be performed to check how much LY3493269 gets into the bloodstream, how long the body takes to…
- Trial name
- NCT04682106
- Testing
- LY3493269, Salcaprozate Sodium
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Multiple-Dose Study of LY3493269 in Healthy Participants
The main purpose of this study is to conduct blood tests to measure how much LY3493269 is in the bloodstream and how the body handles and eliminates LY3493269 when administered orally as test compared to reference formulations in…
- Trial name
- NCT05794243
- Testing
- LY3493269, Sodium Caprate (C10), Salcaprozate Sodium (SNAC)
- Where
- Singapore
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants
The main purpose of this study is to assess the safety and tolerability of pirtobrutinib and to look at the amount of the study drug, pirtobrutinib, that gets into the blood stream and how long it takes the body to get rid of it…
- Trial name
- NCT06181006
- Testing
- Pirtobrutinib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants
The main purpose of this study is to evaluate the absorption, metabolism, and excretion (AME) profiles of pirtobrutinib (LOXO-305), to identify and characterize metabolites of pirtobrutinib (LOXO-305), and to assess the safety…
- Trial name
- NCT06180954
- Testing
- [14C]-LOXO-305, LOXO-305
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Renal Insufficiency
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired kidney function and healthy participants.
- Trial name
- NCT06190678
- Testing
- Pirtobrutinib
- Where
- 5 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants
The main purpose of this study is to compare two different formulations (mixtures) of pirtobrutinib (LOXO-305) in healthy participants.
- Trial name
- NCT06258174
- Testing
- Pirtobrutinib
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Hepatic Insufficiency
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants.
- Trial name
- NCT06190691
- Testing
- Pirtobrutinib
- Where
- 8 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants
The main purpose of this study in healthy participants is to learn more about the safety of LY3509754 and any side effects that might be associated with it.
- Trial name
- NCT04586920
- Testing
- LY3509754, Itraconazole, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
- Trial name
- VIVID-1 (NCT03926130)
- Testing
- Mirikizumab, Ustekinumab
- Where
- 580 sites in United States, Argentina and 32 more
- Volunteers
- 1,158 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in…
- Trial name
- NCT05706506
- Testing
- Tirzepatide
- Where
- 32 sites in United States
- Volunteers
- 152 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment (MCI), Alzheimer Disease
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT05108922
- Testing
- Donanemab, Aducanumab
- Where
- 31 sites in United States
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor…
- Trial name
- monarcHER (NCT02675231)
- Testing
- Abemaciclib, Trastuzumab, Fulvestrant
- Where
- 93 sites in United States, Argentina and 12 more
- Volunteers
- 237 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants
The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled…
- Trial name
- NCT04840901
- Testing
- Lebrikizumab
- Where
- 4 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants.
- Trial name
- NCT05338502
- Testing
- Selpercatinib, Ranitidine, Omeprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Neoplasms, Neoplasm Metastasis
A Study of LY3022855 In Participants With Breast or Prostate Cancer
The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments.
- Trial name
- NCT02265536
- Testing
- LY3022855
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
- Trial name
- NCT03126591
- Testing
- Olaratumab, Pembrolizumab (KEYTRUDA®)
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company